1Hazama Y, Matsuhisa M, Ohtoshi K, et al. Beneficial effects of nateglinide on insulin resistance in type 2 diabetes. Diabetes Res Clin Praet 2006,71(3) :251- 5.
4Taki H, Maki T, Iso T, et al. Postmarketing study ofnateglinide in Japan: treatment of medication - naive patients with type 2 diabetes.Adv Ther 2005;22(6) :621 - 35.
5Gonzalez - Ortiz M, Hernandez - Salazar E. Martinez - Abundis E, Effect of the administration of a single dose of nateglinide on insulin secretion at two different concentrations of glucose in healthy individuals. J Diabetes Complications 2005 ; 19(6):356 - 60.
6Yin J, Yang G. Chen Y. Rapid and efficient chiral separation ofnateglinide and its L-enantiomer on monolithic molecularly imprinted polymers. J Chromatogr A 2005 ; 1090 ( 1 - 2) : 68 - 75.
7Niemi M, Backman JT.Juntti - Patinen L, et al. Coadministration ofgemfibrozil and itraconazole has only a minor effect on the phar-macokinetics of the CYP2C9 and CYP3A4 substrate nateglinide. Br J Clin Pharmacol 2005, 60(2) :208 - 17.
9Abrahamian H, Francesconi M, Loiskandl A, et al. Evaluation of a new insulinotropic agent by using an innovative technology; efficacy and safety of nateglinide determined by continuous glucose monitoring.Diabetes Technol Ther 2004, 6(1) :31 - 7.
10Gerich J, Raskin P, Jean - Louis L et al. PRESERVE - beta:two- year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care. 2005, 28 (9):2093- 2099.
二级参考文献33
1[2]Hu S, Wang S, Fanelli F, et al. Pancreatic β - cell K + ATP channels activity and membrane - binding studies with nateglinide a comparison with sulfonylureas and repaglinide[J]. J Pharmacol Exp Ther, 2000,293 (2): 444.
2[3]Choudhury S, Hirschberg Y, Filkipek R, et al. Single - dose pharmacokinetics of nateglinide in subjects with hepatic cirrhosis[J] . J Clin Pharmacol,2001,40( 6) :634.
3[4]Ikenoue T, Okazaki K, Fujitani S, et al. Effect of a new hypoglyce micagent, A - 4166 [( - )-N-( trans-4-isopropyl-cyclo-hexanecarbonyl )-D-phenylalanine], on postprandial blood glucose excursion:comparison with voglibose and glibenclamide [J]. Biol Pharm Bull, 1997,20 (4): 354.
4[5]Akiyoshi M, Okazaki k, Tsuchiya Y, et al. Hypoglycemic effect of a novel antidiabetic agent, Ay4166, in normal and diabetic rats[J] . Kiso To Rinsho, 1997,31 (5) :1 725.
5[6]A Laghmich. Long term effects of glibenclamide and nateglinide upon pancreatic islet function in normal and diabetic rats[J].Pharmacological Research, 1999,40(6): 475.
6[7]Shaji Fujitani. Somatostatin and insulin secretion due to conmon mechanisms by a new hyopglycemic agent A -4166,in pefused rat pancreas[J]. Metabolise, 1996,145(2): 184.
7[8]Shiling Hu. Tissue selectivity of antidiabetic agent nateglinide;study on cardiovascular and β cell K + ATP channels [J]. J Pharmacol Exp Ther , 1999,291(3): 1 372.
8[10]Adel H Karara, Beth E Dunning,James F Mcleod. The effect of food on the oral bioavailability and the pharacodynamic actions of the insulinotropic agent nateglinide in healthy subjects[J]. J Clin Pharmacol , 1999,39: 172.
9[12]Okanoto M, Akai H, Ide M, et al. Single oral dose toxicity study of AY4166 in beagle dogs[J]. Jpn Pharmcol Ther, 1997,25 (Supple): 9.
10[13]Okazaki S, Ikezaki S, Yamazaki S, et al. A 12 - month repeated oral dose toxicity study of AY4166 in rats[J]. Jpn Pharmacol Ther, 1997,25 (Supple) :63.
8Taki H, Maki T, Iso T, et al. Postmarketing study Ornate-glinide in Japan:treatment of medication-naive patients with type -diabetes[J]. Adv Ther,2005,22(6) :621 - 635.
9Yin J, Yang G,Cben Y. Rapid and efficient chiral separation of nateglinide arid its L-enantiomer on monolithic molecularly imprinted polymers[J]. J Chromatogr A, 2005,1090 ( 1 ) : 68- 75.
10Gerieh J, Raskin P,Jcan- Louis L, et al. PRESERVE- beta: Two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin[J]. Diabetes Care,2005,28(9):2 093-2 099.
